What is HC Wainwright’s Estimate for TERN Q1 Earnings?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Terns Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Neutral” rating and a $7.50 price objective on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.28) per share.

A number of other analysts have also recently weighed in on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $26.00 price target (up from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. Oppenheimer assumed coverage on Terns Pharmaceuticals in a research report on Thursday, October 31st. They issued an “outperform” rating and a $82.00 price objective on the stock. Finally, JMP Securities upped their price target on Terns Pharmaceuticals from $15.00 to $20.00 and gave the company a “market outperform” rating in a research note on Tuesday, September 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Terns Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.25.

Terns Pharmaceuticals Stock Down 5.4 %

Shares of TERN opened at $6.78 on Thursday. Terns Pharmaceuticals has a 12 month low of $3.46 and a 12 month high of $11.40. The stock has a market cap of $476.91 million, a price-to-earnings ratio of -5.75 and a beta of -0.32. The company has a 50-day moving average price of $8.08 and a two-hundred day moving average price of $7.46.

Insider Transactions at Terns Pharmaceuticals

In related news, Director Jill M. Quigley sold 17,235 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $10.00, for a total value of $172,350.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $150,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Terns Pharmaceuticals news, Director Hongbo Lu purchased 476,190 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $10.50 per share, for a total transaction of $4,999,995.00. Following the purchase, the director now owns 476,190 shares in the company, valued at approximately $4,999,995. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jill M. Quigley sold 17,235 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $10.00, for a total value of $172,350.00. Following the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $150,000. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.10% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in shares of Terns Pharmaceuticals by 40.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock worth $13,131,000 after buying an additional 578,500 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Terns Pharmaceuticals by 56.8% in the second quarter. Bank of New York Mellon Corp now owns 176,673 shares of the company’s stock valued at $1,203,000 after buying an additional 64,018 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Terns Pharmaceuticals by 127.9% during the first quarter. Russell Investments Group Ltd. now owns 632,965 shares of the company’s stock worth $4,152,000 after buying an additional 355,224 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Terns Pharmaceuticals by 21.1% during the second quarter. Point72 Asset Management L.P. now owns 2,690,376 shares of the company’s stock worth $18,321,000 after buying an additional 469,176 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Terns Pharmaceuticals by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,199,006 shares of the company’s stock valued at $14,425,000 after acquiring an additional 11,535 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.